6月24日 - ** 瑞士生物技术公司MoonLake Immunotherapeutics（MLTX.O）的股价周三早盘下跌9.9%，至19.12美元，此前该公司定价完成了一笔2亿美元的后续融资
** MLTX周二晚间以每股20美元的价格售出1000万股 (link) 股票（含100万股预先注资认股权证），较最后成交价折让5.7%
** 周一，MLTX股价飙升15%，收于22.16美元，此前该公司公布了针对脓疱性汗腺炎（一种会导致皮损和瘢痕形成的慢性皮肤病）的sonelokimab后期临床试验第52周结果 (link)
** 该公司随后于周一收盘后宣布 (link) 将进行1.5亿美元的股票发行
** MLTX计划将本次股权融资的净收益用于资助索内洛基马布（sonelokimab）的研究、开发、商业化前及商业化活动，并用于一般用途
** Leerink、古根海姆、坎托菲茨杰拉德和LifeSci Capital担任联合簿记管理人
** 受周三这一举措影响，该股年内累计涨幅约45%
** 据LSEG数据显示，16家券商平均评级为“买入”，目标价中位数为30美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.